Prosecution Insights
Last updated: April 17, 2026
Application No. 17/115,749

ALL-IN ONE SYRINGE ASSEMBLY FOR BLOOD DRAWS AND MEDICINE DELIVERY TO PATIENTS

Final Rejection §103
Filed
Dec 08, 2020
Examiner
CERIONI, DANIEL LEE
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
unknown
OA Round
6 (Final)
65%
Grant Probability
Moderate
7-8
OA Rounds
3y 9m
To Grant
93%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
485 granted / 749 resolved
-5.2% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
81 currently pending
Career history
830
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
40.4%
+0.4% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
30.5%
-9.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 749 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Notice of Amendment In response to the amendment(s) filed on 3/5/26, amended claim(s) 1 and 10, and canceled claim(s) 3 is/are acknowledged. The following new and/or reiterated ground(s) of rejection is/are set forth: Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 4, 10, and 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Application Publication No. 2018/0221578 to Hopkins in view of U.S. Patent Application Publication No. 2018/0078707 to Loonan. For claim 1, Hopkins discloses a syringe assembly (Abstract) comprising: a syringe (Examiner’s Note: made up of the elements that it is recited as being) including a cylindrical body (312/412) (Figs. 17-31) (para [0093] and [017]) with a luer at a first end (320/420) (Figs. 17-31) (para [0096] and [110]) and a plunger opening at a second end (unlabeled, but as can be seen in Figs. 18 and 25), said luer including an exit opening (unlabeled, but as can be seen in Figs. 19-23 and 26-31); a plunger unit (Examiner’s Note: defined by the elements it includes) including an adapter portion (generally the adapter structure that encompasses 349, 354, 356, 360, 362 / 449, 454, 456, 460, 462) (Figs. 21-22 and 28-29) (para [0095], [0098], [0103], [0109], [0111], and [0113]) and a receiving cavity (318/418) (Figs. 21-22 and 28-29) (para [0103] and [0112]), a first end of said adapter portion retaining a piston (354/454) (Figs. 21-22 and 28-29) (para [0095] and [0109]), said plunger unit insertable into a syringe opening and slidable within said cylindrical body during which said piston creates a fluid seal with an interior surface of said cylindrical body (as can be seen in Figs. 17-31) (also see para [0095], [0098], [0109], and [0113]), said adapter portion including a channel (356/456) (Figs. 21-22 and 28-29) (para [0098] and [0113]) extending along a length thereof to an opening at a bottom of said receiving cavity, said adapter portion for insertion of an intermediary connector or valve (360/460) (Figs. 18 and 25) (para [0098] and [0113]), said piston configured to (Examiner’s Note: functional language, i.e., capable of) frictionally interact with an inner surface of said cylindrical body to create a vacuum therewithin (see para [0095], [0098], [0109], and [0113]) and prevent said plunger unit from disengaging said cylindrical body of said syringe proximate said second end of said syringe (see either of 345 or 347 in Fig. 22 when 354/454 is pushed past these point(s)) (also see para [0095], [0098], [0109], and [0113]); and a cannula (343/443) secured at one end within said luer (as can be seen in Figs. 17-31) and extending into said piston (para [0098] and [0113]) and extendable into said channel as said plunger unit is inserted farther into said syringe (para [0098] and [0113]). Hopkins does not expressly disclose that the cylindrical body is a tapered body, said body having an inner surface and outer surface, and a taper along an entire length of said inner surface of said tapered body progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer; and wherein said tapered body prevents said plunger unit from exiting said syringe and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created. However, Loonan teaches that the cylindrical body is a tapered body (para [0045]) (also see para [0014] and [0016]-[0017]), said body having an inner surface (“inner surface,” para [0016]) and outer surface (“outer surface,” para [0016]), and a taper (“tapered,” para [0014] and [0016]-[0017]) along an entire length of said inner surface of said tapered body (“…tapered from the distal end towards the proximal end of the barrel body,” para [0016]-[0017]) progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer (as can be seen in Fig. 5) (para [0045]) (also see para [0044]); and wherein said tapered body prevents said plunger unit from exiting said syringe (para [0013]-[0014]) and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created (para [0047]). It would have been obvious to a skilled artisan to modify Hopkins such that the cylindrical body is a tapered body, said body having an inner surface and outer surface, and a taper along an entire length of said inner surface of said tapered body progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer; and wherein said tapered body prevents said plunger unit from exiting said syringe and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created, in view of the teachings of Loonan, for the obvious advantage of preventing “unwanted suction or spillage of the contents” (see Abstract of Loonan). For claim 4, Hopkins, as modified, further discloses wherein said tapered body is cylindrical and said piston is circular (as can be seen in Figs. 17-31). For claim 10, Hopkins discloses a syringe assembly (Abstract) comprising: a syringe (Examiner’s Note: made up of the elements that it is recited as being) including a cylindrical body (312/412) (Figs. 17-31) (para [0093] and [017]) with a luer at a first end (320/420) (Figs. 17-31) (para [0096] and [110]) and a plunger opening at a second end (unlabeled, but as can be seen in Figs. 18 and 25), said luer including an exit opening (unlabeled, but as can be seen in Figs. 19-23 and 26-31); a plunger unit (Examiner’s Note: defined by the elements it includes) including an adapter portion (generally the adapter structure that encompasses 349, 354, 356, 360, 362 / 449, 454, 456, 460, 462) (Figs. 21-22 and 28-29) (para [0095], [0098], [0103], [0109], [0111], and [0113]) and a receiving cavity (318/418) (Figs. 21-22 and 28-29) (para [0103] and [0112]), a first end of said adapter portion retaining a piston (354/454) (Figs. 21-22 and 28-29) (para [0095] and [0109]), said plunger unit insertable into said syringe and slidable within said cylindrical body during which said piston creates a fluid seal with an interior surface of said cylindrical body (as can be seen in Figs. 17-31) (also see para [0095], [0098], [0109], and [0113]), said adapter portion including a channel (356/456) (Figs. 21-22 and 28-29) (para [0098] and [0113]) extending along a length thereof to an opening at a bottom of said receiving cavity, said adapter portion for insertion of an intermediary connector or valve (360/460) (Figs. 18 and 25) (para [0098] and [0113]), said piston configured to (Examiner’s Note: functional language, i.e., capable of) frictionally interact with an inner surface of said cylindrical body to prevent said plunger unit from disengaging said tapered body of said syringe proximate said second end of said syringe (see either of 345 or 347 in Fig. 22 when 354/454 is pushed past these point(s)) (also see para [0095], [0098], [0109], and [0113]); and a cannula (343/443) secured at one end within said luer (as can be seen in Figs. 17-31) and extending into said piston (para [0098] and [0113]) and extendable into said channel as said plunger unit is Hopkins does not expressly disclose that the cylindrical body is a tapered body, a taper along an entire length of said tapered body progressively increasing from a smaller diameter at said plunger opening to a larger diameter at said luer. Hopkins does not expressly disclose that the cylindrical body is a tapered body, said body having an inner surface and outer surface, and a taper along an entire length of said inner surface of said tapered body progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer; and wherein said tapered body prevents said plunger unit from exiting said syringe and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created. However, Loonan teaches that the cylindrical body is a tapered body (para [0045]) (also see para [0014] and [0016]-[0017]), said body having an inner surface (“inner surface,” para [0016]) and outer surface (“outer surface,” para [0016]), and a taper (“tapered,” para [0014] and [0016]-[0017]) along an entire length of said inner surface of said tapered body (“…tapered from the distal end towards the proximal end of the barrel body,” para [0016]-[0017]) progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer (as can be seen in Fig. 5) (para [0045]) (also see para [0044]); and wherein said tapered body prevents said plunger unit from exiting said syringe (para [0013]-[0014]) and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created (para [0047]). It would have been obvious to a skilled artisan to modify Hopkins such that the cylindrical body is a tapered body, said body having an inner surface and outer surface, and a taper along an entire length of said inner surface of said tapered body progressively increasing from a smaller inner diameter at said plunger opening to a larger inner diameter at said luer, wherein said tapered body prevents said plunger unit from exiting said syringe and when said plunger unit is in a fully extended locked position within said syringe a vacuum in said syringe is created, in view of the teachings of Loonan, for the obvious advantage of preventing “unwanted suction or spillage of the contents” (see Abstract of Loonan). For claim 13, Hopkins, as modified, further discloses wherein said tapered body is cylindrical and said piston is circular (as can be seen in Figs. 17-31). Response to Arguments Applicant’s arguments have been considered but are moot because the arguments do not address the new grounds of rejection necessitated by Applicant’s amendments presented in the response filed 3/5/26. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL LEE CERIONI whose telephone number is (313) 446-4818. The examiner can normally be reached M - F 8:00 AM - 5:00 PM PT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Chen can be reached on (571) 272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANIEL L CERIONI/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Dec 08, 2020
Application Filed
Apr 07, 2023
Non-Final Rejection — §103
Oct 05, 2023
Response Filed
Oct 20, 2023
Final Rejection — §103
Apr 25, 2024
Request for Continued Examination
Apr 26, 2024
Response after Non-Final Action
Aug 06, 2024
Non-Final Rejection — §103
Feb 12, 2025
Response Filed
Feb 15, 2025
Final Rejection — §103
May 20, 2025
Request for Continued Examination
May 23, 2025
Response after Non-Final Action
Sep 03, 2025
Non-Final Rejection — §103
Mar 05, 2026
Response Filed
Mar 16, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599338
DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY
2y 5m to grant Granted Apr 14, 2026
Patent 12601641
Temperature Estimation Method, Temperature Estimation Program and Temperature Estimation Device
2y 5m to grant Granted Apr 14, 2026
Patent 12594062
FLUID COLLECTION ASSEMBLIES INCLUDING AN EXTENSION
2y 5m to grant Granted Apr 07, 2026
Patent 12588949
LASER ABLATION WITH ELECTROMAGNETIC ENERGY FEEDBACK
2y 5m to grant Granted Mar 31, 2026
Patent 12582344
WIRELESS STIMULATION PROBE DEVICE FOR WIRELESS NERVE INTEGRITY MONITORING SYSTEMS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
65%
Grant Probability
93%
With Interview (+28.6%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 749 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month